COVID-19 infection in patients with acute leukemia; Istanbul experience

Basit Öğe Kaydı
dc.authorid0000-0003-1237-8281
dc.contributor.authorBüyüktaş, Deram
dc.contributor.authorAcar, Kadir
dc.contributor.authorSucak, Gülsan
dc.contributor.authorToptaş, Tayfur
dc.contributor.authorKapucu, İrem
dc.contributor.authorBeköz, Hüseyin
dc.contributor.authorErdem, Simge
dc.contributor.authorNalcacı, Meliha
dc.contributor.authorAtalay, Figen
dc.contributor.authorAkay, Olga Meltem
dc.contributor.authorFerhanoğlu, Burhan
dc.date.accessioned2021-11-02T11:09:29Z
dc.date.available2021-11-02T11:09:29Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractCoronavirus disease 2019 (COVID-19) has led to a global pandemic that has also challenged the management of various other life-threatening conditions, such as malignant disorders. In this study, we present the clinical features and treatment outcomes of twenty-seven COVID-19 positive patients with leukemia across seven different centers in Istanbul. From March 1st to December 31st 2020, 116 patients were diagnosed with acute leukemia. Thirty-two cases with acute lymphocytic leukemia (ALL), 82 cases with acute myeloid leukemia (AML), and 2 cases with mixed phenotype acute leukemia (MPAL) were identified. Of the 27 patients with the COVID-19 infection, seven patients had ALL, 19 patients had AML and one patient had MPAL. The mortality rate was 37% among the patients with AML, whereas there were no deaths in the ALL group. The mortality rate of AML patients with the COVID-19 infection was higher compared to cases without the infection (P<0.05). We could not detect any significant difference in the ALL cohort. This study, which includes one of the largest acute leukemia series in literature proved that acute myeloid leukemia patients with the COVID-19 infection have worse outcomes than patients without the infection. The high mortality among patients with acute leukemias hospitalized with COVID-19 highlight the need for aggressive infection prevention, increased surveillance and protective isolation and even modification of the therapy, in case of minimal residual disease (MRD) negativity.
dc.identifier.citationBüyüktaş, D., Acar, K., Sucak, G., Toptaş, T., Kapucu, İ., Beköz, H. ... Ferhanoğlu, B. (2021). COVID-19 infection in patients with acute leukemia; Istanbul experience. American Journal of Blood Research, 11(4), 427-437.
dc.identifier.endpage437
dc.identifier.issn2160-1992
dc.identifier.issue4
dc.identifier.startpage427
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8544
dc.identifier.volume11
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publishere-Century Publishing Corp
dc.relation.ispartofAmerican Journal of Blood Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectCOVID-19
dc.subjectSARS-Cov2
dc.subjectAcute Leukemia
dc.subjectAcute Lymphoblastic Leukemia
dc.subjectAcute Myeloid Leukemia
dc.titleCOVID-19 infection in patients with acute leukemia; Istanbul experience
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Bekoz-Huseyin-2021.pdf
Boyut:
328.47 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu